Literature DB >> 23277700

Contraceptive effect and potential side-effects of deslorelin acetate implants in rats (Rattus norvegicus): preliminary observations.

Claire Grosset1, Stijn Peters, Franck Peron, Joëlle Figuéra, Christelle Navarro.   

Abstract

During the last ten years, numerous species have been treated with deslorelin implants to induce contraception. The aims of the study were 1) to assess contraceptive efficacy of 4.7 mg subcutaneous deslorelin implants in rats, 2) to determine the latency of contraceptive effect, and 3) to determine potential side effects. Three experimental females were implanted and their estrous cycle was studied by vaginal smear. Two weeks after implantation, a male whose fertility was previously assessed with a control female, was introduced into their cage. No female conceived during the 4 mo following implantation. Additionally, 38 pet rats were recruited from clients in practice to test for potential side effects, including 6 males and 32 females with a mean age of 14 mo. Local reaction and transient weight gain during the first 2 wk, as well as behavioral changes were recorded. According to this pilot study, deslorelin implant could be used as a contraceptive method in female rats. The latency period is about 2 wk. Nevertheless, it might be possible to refine the treatment further using hormonal measurements. The duration of contraceptive effect is to be determined in an upcoming study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23277700      PMCID: PMC3384284     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  34 in total

1.  Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.

Authors:  Walid Massoud; Philippe Paparel; Jean-Gabriel Lopez; Paul Perrin; Michele Daumont; Alain Ruffion
Journal:  Int J Urol       Date:  2006-03       Impact factor: 3.369

2.  Repeated use of the GnRH analogue deslorelin to down-regulate reproduction in male cheetahs (Acinonyx jubatus).

Authors:  H J Bertschinger; M Jago; J O Nöthling; A Human
Journal:  Theriogenology       Date:  2006-02-28       Impact factor: 2.740

3.  A quantitative method for assessing stages of the rat estrous cycle.

Authors:  C H Hubscher; D L Brooks; J R Johnson
Journal:  Biotech Histochem       Date:  2005 Mar-Apr       Impact factor: 1.718

4.  Short- to mid-term effects of ovariectomy on bone turnover, bone mass and bone strength in rats.

Authors:  Yan Zhang; Wan-Ping Lai; Ping-Chung Leung; Chun-Fu Wu; Man-Sau Wong
Journal:  Biol Pharm Bull       Date:  2007-05       Impact factor: 2.233

5.  Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.

Authors:  H Okada; Y Inoue; T Heya; H Ueno; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

6.  Characteristics of luteinizing hormone (LH) and testosterone secretion, pituitary responses to LH-releasing hormone (LHRH), and reproductive function in young bulls receiving the LHRH agonist deslorelin: effect of castration on LH responses to LHRH.

Authors:  M J D'Occhio; W J Aspden
Journal:  Biol Reprod       Date:  1996-01       Impact factor: 4.285

7.  Neoplasms and related proliferative lesions in control Sprague-Dawley rats from carcinogenicity studies. Historical data and diagnostic considerations.

Authors:  D N McMartin; P S Sahota; D E Gunson; H H Hsu; R H Spaet
Journal:  Toxicol Pathol       Date:  1992       Impact factor: 1.902

8.  Osteopenia caused by ovariectomy in young female rats and prophylactic effects of 1,25-dihydroxyvitamin D3.

Authors:  B Kohn; R G Erben; H Weiser; W A Rambeck; H Zucker
Journal:  Zentralbl Veterinarmed A       Date:  1991-02

9.  The effects of overfeeding and dietary restriction on Sprague-Dawley rat survival and early pathology biomarkers of aging.

Authors:  K P Keenan; P F Smith; P Hertzog; K Soper; G C Ballam; R L Clark
Journal:  Toxicol Pathol       Date:  1994 May-Jun       Impact factor: 1.902

Review 10.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.